world [3] . In the following season, the seasonal H1N1 virus continued to circulate at a minimal level but eventually became extinct. However, a return and, in some cases, dominance of seasonal H3N2 and influenza B viruses was observed worldwide [4, 5] .
In addition to their antigenic evolution, influenza viruses evolve under drug pressure or natural selection, and new virus populations that are resistant to treatment occasionally evolve and sometimes prevail if viral fitness is maintained [6, 7] . As a result, the use of antiviral drugs like amantadine, an M2-channel inhibitor, has been largely limited due to the surge of amantadine-resistant H3N2 influenza viruses [8] . Neuraminidase inhibitors (NAIs), including oseltamivir and zanamivir, became the drugs of choice for treatment of H3N2 influenza infections [9] . The utility of oseltamivir in treating influenza was jeopardized by the worldwide rapid emergence of oseltamivir-resistant seasonal H1N1 viruses during 2007 through 2009 [6, 7] . Nonetheless, this virus was soon replaced by the H1N1p virus, which is largely sensitive to oseltamivir but resistant to amantadine [10] . This has revived the utility of oseltamivir in treating influenza.
Surveillance studies aimed at investigating the evolution and characteristics of influenza viruses worldwide are essential to early detection of new antigenically variant viruses as well as those with decreased antiviral drug susceptibility to allow informed recommendations for vaccination strategies and therapeutic interventions. Influenza surveillance efforts in the Middle East, including Lebanon, the site of this study, have been very limited. Characterization of influenza viruses in this region is critical to compliment the global effort to monitor and control influenza. The H1N1p influenza virus was first detected in Lebanon in May 2009. One study showed that a large outbreak caused by the pandemic virus occurred in October of the same year in Lebanon [11] . The prevalence of H1N1p viruses in the post-pandemic seasons and their susceptibilities to antiviral drugs is unknown in Lebanon.
The goal of this study was to characterize influenza viruses that circulated in Lebanon during two post-pandemic influenza seasons.
Materials and Methods
Sample Collection Nasal swabs were collected from patients presenting with influenza-like illness (ILI) symptoms (i.e. fever of at least 37.5°, cough, rhinorrhea, myalgia, and headache) at a pediatric clinic in Beirut. One swab was immediately tested using a rapid influenza diagnostic test, Quick-Ex Flu kit (Denka Seiken, Japan), and a second swab was stored in virus transport media at -80° until further analysis.
Virus Isolation and Characterization
100 μl of the swab suspension was inoculated onto Madin-Darby canine kidney (MDCK) cells and incubated at 37° and 5% CO 2 . Influenza virus type and subtype were characterized using cyclingprobe real-time PCR [12] [13] [14] .
RNA Extraction, PCR, and Sequencing
Following RNA extraction and reverse transcription [15, 16] , the HA (HA1 subunit) and neuraminidase (NA) genes were sequenced and aligned using BioEdit software. Phylogenetic trees were constructed using the Neighbor-Joining (MEGA program). Clusters were defined using WHO-designated reference strains [17] . Sequences generated in this study were deposited in the Japanese GenBank database (http://www.ddbj.nig.ac.jp/; accession No. KF000008-62).
Antiviral Drug Susceptibility Testing
Genotypic analysis of the single-nucleotide polymorphisms M2-S31N and NA-H275Y, which confer resistance to amantadine and oseltamivir, respectively, was performed using cycling probe method [12, 13] . In vitro antiviral drug susceptibilities of the isolated viruses were determined by measuring the 50% inhibitory concentrations (IC 50 ) of oseltamivir (Sequoia Research, UK), zanamivir (Sequoia Research, UK), peramivir (Shionogi, Japan), and laninamivir (Daiichi Sankyo, Japan) using a fluorescencebased NA inhibition assay with methylumbelliferone N-acetylneuraminic acid (MUNANA) as the substrate at a final concentration of 0.025 m M [18] . The black bars indicate the 75th percentile + 3 × interquartile range (3 IQR) . Values below the box plot represent mean ± SD. The mean value was calculated from viruses with IC 50 values below the cutoff limit (75th percentile + 3 IQR). Samples with IC 50 greater than the cutoff limit are considered outliers. fig. 2 d) . In summary, the IC 50 values suggest that all influenza A viruses isolated in the study are highly susceptible to NAIs. Influenza B isolates had up to 50-fold higher IC 50 values than influenza A isolates.
Post-Pandemic Influenza in Lebanon
Phylogenetic analysis of the HA genes from H1N1p viruses revealed that the 2010-2011 season belonged to five distinct clusters : 1, 5, 6, 7 and 9 ( fig. 3 a) . Cluster 1 included isolates from the 2009 pandemic outbreak with the exception of one isolate (A/Lebanon/10L-21/2011) from the 2010-2011 season, which had 2 additional mutations (S134T and R265K) in the HA gene. Two isolates (A/Lebanon/10L-34/2011 and A/Lebanon/10L-38/2011) from the 2010-2011 season formed a small cluster, designated cluster 9, characterized by 4 unique mutations (N44D, A267V, G270S, and I272L). None of these mutations belonged to any of the reported antigenic sites. In addition to the 2010-2011 season isolates, cluster 6 also accommodated the 2011-2012 isolates, which accumulated 3 additional HA mutations, including an H144R mutation in the Ca antigenic site and a V158I mutation adjacent to the Sa antigenic site [19] . Overall, the H1N1p viruses analyzed in this study had 6 amino acid mutations in the antigenic sites: 3 in Ca, 2 in Sb, and 1 in Sa, compared with A/California/07/2009. Three of these mutations were not detected in the earlier H1N1p viruses.
To determine the genetic basis of the reduced susceptibility to oseltamivir of the 10L-21 (A/Lebanon/10L-21/ 2011) isolate from the 2010-2011 season and its genetic relatedness to other isolates, we sequenced the NA genes of all H1N1p viruses isolated in this study. In general, the Lebanese H1N1p NA genes had a clustering pattern that corresponded with their counterpart HA clusters and had 5-7 mutations compared with the A/California/07/2009 vaccine strain ( fig. 3 ) . The 10L-21 isolate with reduced susceptibility to oseltamivir belonged to cluster 1 in the NA tree similar to its position in the HA tree. This isolate was characterized by 3 mutations: S247N, N385T, and N386K. The N385T and N386K mutations were located away from the enzyme-active site, suggesting no role in the reduced susceptibility to oseltamivir. The S247N mutation interacts with amino acid residues that in turn interact with oseltamivir and could interfere with stability of the inhibitor in the enzyme-active pocket [20] . The 10L-34 and 10L-38 strains formed a small isolated cluster in the NA tree just like in the HA tree and were characterized by 4 unique mutations: Q313E, T383R, I396T, and S442I.
The HA genes of 8 Lebanese H3N2 influenza viruses collected during the 2011-2012 season were sequenced. All the sequenced viruses were A/Perth/16/2009-like and belonged to the Vic/208 lineage in the HA phylogeny ( fig. 4 ) . Two of the isolates belonged to clade 3A, and the rest belonged to clade 3B, which also contained strains from other Middle Eastern countries. These isolates accumulated 9-10 mutations, including 2 antigenic site A mutations (K144N/D and N145S). In case of influenza B, all of the 11 isolates collected during the 2010-2011 season were sequenced. All of these isolates were Victorialike and belonged to the Brisbane/60 clade ( fig. 5 ). The Lebanese strains had 1-2 mutations compared with the B/Brisbane/60/2008 vaccine strain (2009) (2010) (2011) (2012) .
Discussion
In this study, we found that in the first post-pandemic season (2010-2011), both influenza B and A/H1N1p cocirculated at a similar rate. In the 2011-2012 season, the A/H3N2 virus dominated and the H1N1p virus co-circulated with a lower prevalence. Similar circulation patterns have been reported elsewhere in the world [4, 21] . The extinction of seasonal H1N1 viruses has been suggested to be a consequence of the original antigenic sin, whereby infection with the H1N1p virus boosted the HA stalk antibodies against the seasonal H1N1 virus [22] . A similar phenomenon has been observed when H2N2 pandemic viruses, which emerged in 1957, replaced previously circulating H1N1 viruses. The H2N2 virus circulated for 11 Intervirology 2014; 57:344-352 DOI: 10.1159/000365758 348 years until it was replaced by H3N2 virus in 1968 due to antibodies specific to the retained N2 subtype [23] .
The H1N1p viruses continued to evolve, accumulating mutations in antigenic sites, but remained antigenically similar to the A/California/07/2009 vaccine strain.
In the post-pandemic 2010-2011 season, H1N1p viruses collected in Lebanon were diverse, belonging to multiple clusters, suggesting multiple introductions of this virus into Lebanon. This was in contrast to mostly homologous H1N1p viruses that we detected in previous ¥ Viruses with the S247N mutation. In the NA tree, only reference samples for which the NA gene sequence was available in the GenBank database are included.
work during the pandemic [11] . In the case of H3N2, all viruses from the 2011-2012 season sequenced in this study belonged to the A/Victoria/208/2011-like lineage, and most of them fell into clade 3B. The Lebanese isolates closely resembled WHO-designated reference strains A/Stockholm/18/2011 and A/England/259/2011 which exhibited 64-and 32-fold reduction, respectively, in their HA inhibition (HAI) titers of sera raised against the A/Victoria/210/2009 vaccine strain [17] . These viruses accumulated several mutations, including 3-4 in the antigenic sites compared with the vaccine strain which explains the antigenic drift marked reduction in their HAI titers.
The prevalence of oseltamivir-resistant H1N1p viruses remained low worldwide in the post-pandemic period, albeit at a slight increase from their level during the pandemic period [24] [25] [26] . Nonetheless, the rate of oseltamivir resistance is much higher among high-risk groups such as immunocompromised patients, and clusters of high community transmission rates have been reported [25, 27] . Hurt et al. [28] reported a significant increase in the frequency H275Y oseltamivir-resistant H1N1p virus- es in a community in Australia. These resistant viruses had three additional NA mutations, V241I, N369K, and N386S, that were suggested to compensate for the destabilizing effect of the H275Y mutation and could, therefore, be permissive for fixing the H275Y mutation in the population. All of the 2011-2012 season H1N1p viruses isolated in Lebanon, despite lacking the H275Y mutation, had these potentially permissive mutations, and 55% of the 2010-2011 isolates had 2 of these mutations (V241I and N369K). Collectively, these data suggest that H1N1p viruses have the capacity to accommodate the H275Y with potentially minimal burden on their fitness. We also detected one H1N1p isolate with a 4-fold reduced oseltamivir IC 50 , due to an NA-S247N mutation, in a patient prior to prescription of oseltamivir. This mutation was reported in 10 and 30% of H1N1p viruses isolated in Australia and Singapore, respectively, during the same period [20] . The Lebanese S247N isolate was phylogenetically distinct from those isolated in Australia and Singapore. Of note, this mutation was also reported in H5N1 viruses isolated in Laos, reducing their susceptibility to oseltamivir by 24-fold [29] . These reports suggest that the S247N mutation could be naturally selected without antiviral drug pressure and is transmissible. While the IC 50 values of S247N viruses are well below the biological drug concentrations of oseltamivir [20] , the possibility that this mutation gets selected in viruses with the H275Y mutation is of concern. An isolate with dual NA-S247N and -H275Y mutations has been already reported and was shown to result in a 6,000-fold increase in oseltamivir IC 50 [20] , rendering treatment with oseltamivir ineffective.
In conclusion, given the diversity of influenza viruses and the potential for rapid emergence of antiviral drugresistant strains, it is essential to closely monitor influenza viruses both by phenotypic and genotypic assays to quickly identify such emerging mutations. Since the worldwide distribution of antiviral drug-resistant influenza strains varies, it is important to strengthen influenza surveillance at local and regional levels. Such information is critical for maintaining the effectiveness of antiviral drugs for both prophylaxis and treatment of influenza infections.
